ReNAP Therapeutics

ReNAP Therapeutics is a private Iranian biotechnology company focused on messenger RNA medicines and lipid nanoparticle delivery technologies. The company is best known for COReNAPCIN, an mRNA COVID-19 vaccine candidate encoding the prefusion-stabilized SARS-CoV-2 spike protein, which has been evaluated in a randomized Phase 1 booster study in healthy adults. Beyond vaccines, ReNAP appears to be developing broader mRNA-enabled capabilities spanning plasmid DNA, mRNA, LNP formulation, recombinant proteins, and exploratory cell therapy applications such as mRNA-LNP-generated anti-CD19 CAR-NK cells. The company positions itself as an mRNA platform developer serving infectious disease, immunotherapy, cancer, and genetic medicine opportunities. Publicly available evidence suggests it remains an active early-stage platform biotech rather than a commercial-stage company.